Palisade Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Palisade Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,050	Closed	-$236K	–	428
2021 Q3	$236K	Buy	3,050 +550	+22%	+$43.4K	0.01%	394
2021 Q2	$209K	Sell	2,500 -1,000	-29%	-$79.3K	﹤0.01%	393
2021 Q1	$264K	Buy	+3,500	New	+$286K	0.01%	360
2020 Q4	–	Sell	-3,000	Closed	-$228K	–	386
2020 Q3	$228K	Buy	+3,000	New	+$304K	0.01%	376
2017 Q1	–	Sell	-2,598	Closed	-$215K	–	436
2016 Q4	$215K	Sell	2,598 -1,333	-34%	-$115K	0.01%	445
2016 Q3	$364K	Buy	+3,931	New	+$370K	0.01%	514
2016 Q2	–	Sell	-2,429	Closed	-$200K	–	539
2016 Q1	$200K	Sell	2,429 -85	-3%	-$6.92K	0.01%	518
2015 Q4	$263K	Buy	2,514 +24	+1%	+$2.51K	0.01%	501
2015 Q3	$262K	Buy	2,490 +22	+0.9%	+$2.94K	0.01%	499
2015 Q2	$338K	Buy	+2,468	New	+$306K	0.01%	493

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Palisade Capital Management's BMRN Position: Q4 2021 in Review

Palisade Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2021, closing a stake of 3,050 shares — an estimated $236K sold.

Palisade Capital Management first reported a position in BMRN in Q2 2015 and held it in 10 quarters. The position peaked at $364K in Q3 2016. 556 funds tracked by Wall St. Rank hold BMRN as of Q4 2021.

Palisade Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Palisade Capital Management sold 3,050 BioMarin Pharmaceuticals shares in Q4 2021, an estimated $236K.
Palisade Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2015 and held it in 10 quarters.
Palisade Capital Management's BioMarin Pharmaceuticals position peaked at $364K in Q3 2016.
556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2021.

Based on Palisade Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.